<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883918</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-aGVHD-001</org_study_id>
    <nct_id>NCT04883918</nct_id>
  </id_info>
  <brief_title>ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)</brief_title>
  <official_title>Evaluation of Safety and Efficacy of ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASC Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute GVHD following allogeneic HCT is an immune-triggered process, leading to profound&#xD;
      immune dysregulation and organ dysfunction. Despite pivotal advances, aGVHD is one of the&#xD;
      leading causes of non-relapse mortality in patients undergoing HCT.&#xD;
&#xD;
      Placenta-derived DSCs, isolated from the fetal membrane of maternal origin, are a type of&#xD;
      stromal cells with well-characterized immunosuppressive properties. The current study is&#xD;
      designed to assess the safety and efficacy of 4 intravenous (IV) doses of ASC930 DSC cells in&#xD;
      aGVHD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) at Day 28</measure>
    <time_frame>28 days post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events, and serious AEs</measure>
    <time_frame>30 days post-infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) at DAY 180</measure>
    <time_frame>180 days post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate at DAY 180</measure>
    <time_frame>180 days post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) at Day 28 and Day 180</measure>
    <time_frame>28 and 180 days post-infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute-graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>ASC930</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASC930</intervention_name>
    <description>4 intravenous doses of ASC930</description>
    <arm_group_label>ASC930</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants â‰¥ 2 months of age&#xD;
&#xD;
          -  Diagnosis of aGVHD grade II-IV following allogeneic HSCT according to standard&#xD;
             criteria (Harris, 2016).&#xD;
&#xD;
          -  Diagnosis of SR-aGVHD according to Mohty (2020)&#xD;
&#xD;
          -  Meet one of the following criteria:&#xD;
&#xD;
               -  Participants who are Ruxolitinib-refractory, according to Mohty (2020)&#xD;
&#xD;
               -  Participants who are not eligible for SOC therapy&#xD;
&#xD;
               -  Participants who agree to receive ASC930 as a second-line therapy&#xD;
&#xD;
          -  Karnofsky/Lansky Performance Status of at least 30 at the time of study entry&#xD;
&#xD;
          -  Minor participants must be capable of giving written assent as appropriate per the&#xD;
             applicable age (per local regulatory requirements).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of active Hepatic Sinusoidal Obstruction Syndrome (SOS)&#xD;
&#xD;
          -  Presence of an active uncontrolled infection&#xD;
&#xD;
          -  Active treatment for a hyprecoagulation disorder&#xD;
&#xD;
          -  Evidence of diffuse alveolar hemorrhage or other active pulmonary disease&#xD;
&#xD;
          -  Evidence of encephalopathy as defined by a change in mental status since the onset of&#xD;
             aGVHD&#xD;
&#xD;
          -  Evidence of relapse of malignancy&#xD;
&#xD;
          -  Receival of agents other than steroids for primary treatment of aGVHD&#xD;
&#xD;
          -  Severe allergic history to cell-based products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Manager, PhD</last_name>
    <phone>(408) 495-3891</phone>
    <email>gil.gonen@asctherapeutics.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

